Thomas C. Pearson is a scholar working on Immunology, Genetics and Hematology.
According to data from OpenAlex, Thomas C. Pearson has authored 276 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Immunology, 76 papers in Genetics and 60 papers in Hematology. Recurrent topics in Thomas C. Pearson's work include T-cell and B-cell Immunology (66 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Immune Cell Function and Interaction (53 papers). Thomas C. Pearson is often cited by papers focused on T-cell and B-cell Immunology (66 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Immune Cell Function and Interaction (53 papers). Thomas C. Pearson collaborates with scholars based in United States, United Kingdom and Canada. Thomas C. Pearson's co-authors include Christian P. Larsen, Andrew Adams, Peter S. Linsley, G. Wetherley‐Mein, Diane Z. Alexander, Shannon C. Ritchie, Rose Hendrix, Eric T. Elwood, Rafi Ahmed and Megan M. Durham and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.
In The Last Decade
Thomas C. Pearson
272 papers
receiving
15.9k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
19961.2k citationsChristian P. Larsen, Rose Hendrix et al.profile →
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
1997649 citationsChristian P. Larsen, Thomas C. Pearson et al.profile →
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
2005549 citationsChristian P. Larsen, Thomas C. Pearson et al.American Journal of Transplantationprofile →
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
2010424 citationsThomas C. Pearson et al.American Journal of Transplantationprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Thomas C. Pearson
Since
Specialization
Citations
This map shows the geographic impact of Thomas C. Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Pearson more than expected).
Fields of papers citing papers by Thomas C. Pearson
This network shows the impact of papers produced by Thomas C. Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Pearson. The network helps show where Thomas C. Pearson may publish in the future.
Co-authorship network of co-authors of Thomas C. Pearson
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas C. Pearson.
A scholar is included among the top collaborators of Thomas C. Pearson based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Thomas C. Pearson. Thomas C. Pearson is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Tomlanovich, Stephen J., Thomas C. Pearson, & Lorenzo Gallon. (2007). EVOLVING STRATEGIES FOR IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A REVIEW OF RECENT CLINICAL TRIALS*. 9(7). 275–280.1 indexed citations
6.
Pearson, Thomas C., et al.. (2007). Protecting Global Financial Market Stability and Integrity: Strengthening SEC Regulation of Hedge Funds. North Carolina Journal of International Law. 33(1). 1.2 indexed citations
7.
Pearson, Thomas C., et al.. (2007). Investigations, Inspections, and Audits in the Post-SOX Environment. Nebraska law review. 86(1). 3.1 indexed citations
8.
Pearson, Thomas C.. (2006). Preparing Multinational Companies for Transfer Pricing Audits of Intangibles. 2(2). 159–200.3 indexed citations
9.
Pearson, Thomas C.. (2005). Creating Accountability: Increased Legal Status of Accounting and Auditing Authorities in the Global Capital Markets (U.S. and EU). North Carolina Journal of International Law. 31(1). 65.1 indexed citations
10.
Halloran, Philip F., Yves Vanrenterghem, Thomas C. Pearson, et al.. (2005). Belatacept (LEA29Y) as part of a CNI-free regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss: Comparison with cyclosporine A. American Journal of Transplantation. 5. 397–397.5 indexed citations
Onami, Thandi M., Laurie E. Harrington, Matthew A. Williams, et al.. (2002). Dynamic Regulation of T Cell Immunity by CD43. The Journal of Immunology. 168(12). 6022–6031.86 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.